Research programme: Alzheimer's disease gene therapy - Amarantus Bioscience Holdings/University of LeipzigAlternative Names: P16 gene therapy - Amarantus Bioscience Holdings/University of Leipzig
Latest Information Update: 07 Aug 2014
At a glance
- Originator University of Leipzig
- Developer Amarantus Bioscience Holdings; University of Leipzig
- Class Gene therapies
- Mechanism of Action Cell cycle modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Alzheimer's disease